缓解基于多种免疫衰竭状态的检查点抑制的非遗传性抵抗
Irina Kareva1,2, Jana L Gevertz3
1Quantitative Pharmacology Department, EMD Serono, Merck KGaA, Billerica, MA, USA. irina.kareva@emdserono.com.
NPJ systems biology and applications
|February 9, 2024
概括
了解免疫细胞疲劳状态是改善癌症治疗的关键. 调节药物剂量和频率,就像计量剂量一样,可以克服对免疫检查点抑制剂的耐药性.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 数学生物学 数学生物学
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗,但面临着不响应和获得抵抗的挑战.
- T细胞表现出不同的疲劳状态:功能性,可逆性和终极性,影响治疗效果.
- 受炎症或抗原暴露影响的非遗传性耐药性机制,有助于ICI治疗失败.
研究的目的:
- 探索免疫细胞耗尽状态对ICI治疗反应的理论影响.
- 调查剂量和剂量频率如何影响对ICI的耐药性.
- 通过剂量调节来确定减轻ICI耐药性的潜在策略.
主要方法:
- 开发一个概念数学模型,整合免疫细胞枯竭表型.
- 将概念模型与标准的两部分制药动力学 (PK) 模型结合起来.
- 模拟分析不同剂量策略 (高剂量/低频与计量) 对治疗结果的影响.
主要成果:
- 通过改变药物剂量和服用频率,可以减轻对ICI耐药性的出现.
- 标准的PK指标与治疗结果没有可靠的相关性.
- 炎症水平触发过渡到终极耗尽的T细胞,极大地影响治疗成功.
- 预计计计量学类型的剂量策略在不同患者群体中有效,与标准的高剂量疗法不同.
- 抗性缓解即使在长时间的抗原暴露引发过渡时也是如此.
结论:
- 免疫细胞枯竭表型显著影响ICI治疗反应和耐药性.
- 剂量调节,特别是与计量学类似的策略,为克服ICI耐药性提供了一个有希望的方法.
- 未来的治疗设计应该考虑超越传统PK参数的免疫细胞状态动态.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524


